GLP-1 receptor agonists

It looks like we'll see oral GLP-1 drugs on the market by 2026, with Eli Lilly reporting impressive results from a large, robust 72-week trial that saw obese patients lose an average of 27.3 lb, or 12.4% of their body weight, with a once-daily pill.

Byproducts from gut bacteria breaking down tryptophan, a dietary amino acid, can restore hormone-secreting gut cells reduced by obesity, a new study found. It opens the door to a natural, side-effect-free alternative to GLP-1 drugs like Ozempic.

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial. In the trial, participants lost an average of 3% fat mass in two weeks.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost fitness and can cause serious muscle loss, potentially undermining the long-term health benefits of slimming down.

A current weight-loss and diabetes drug has become a surprise candidate for effective migraine treatment, with a new study showing that the GLP-1 receptor agonist provided significant relief to sufferers of these debilitating, severe headaches.

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating cognitive decline, and it furthers our understanding of why GLP-1 weight loss drugs appear to provide a shield against Alzheimer's disease.

A new drug from pharma company Amgen shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in the largest clinical trial yet, with nearly 90% of participants losing at least 5% of their body weight. The results strengthen its case for FDA approval.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.

The first once-daily oral GLP-1 medication could be on shelves by this time next year, making the weight-loss drug easier to take and potentially cheaper. In the race to be the first, Novo Nordisk has scored a huge win, while Pfizer has failed again.

GLP-1 drugs have reportedly changed people's relationship with more than just food, but it's been largely anecdotal. Now, there's evidence that Ozempic blocks alcohol cravings – which could be a game-changer for people who want to cut back on booze.

There's a growing body of evidence that gold nanoparticles can trigger significant weight loss that targets fat, without affecting muscles, plus heal organs and improve blood-glucose levels. A new study makes a strong case for the first-ever human trial.